Regulation of Sexual Dimorphism by Sry

Donahoe, Patricia K.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
• Type: Research Project (R01)
• Project #: 5R01HD030812-03
• Application #: 2203151
• Study Section: Reproductive Biology Study Section (REB)
• Project Start: 1993-08-01
• Project End: 1997-11-30
• Budget Start: 1995-12-01
• Budget End: 1996-11-30
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: Massachusetts General Hospital
• City: Boston
• State: MA
• Country: United States
• Zip Code: 02199

Publications

Haqq, C M; Donahoe, P K (1998) Regulation of sexual dimorphism in mammals. Physiol Rev 78:1-33

Shah, P C; Simpson, B B; Donahoe, P K (1996) Mullerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies. Semin Pediatr Surg 5:182-90

Kurian, M S; de la Cuesta, R S; Waneck, G L et al. (1995) Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo. Clin Cancer Res 1:343-9

Peters, R; King, C Y; Ukiyama, E et al. (1995) An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction. Biochemistry 34:4569-76

Haqq, C M; King, C Y; Ukiyama, E et al. (1994) Molecular basis of mammalian sexual determination: activation of Mullerian inhibiting substance gene expression by SRY. Science 266:1494-500